Lineage Cell Therapeutics (LCTX) Current Deferred Revenue (2010 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Current Deferred Revenue of $1.7 million for Q1 2026, down 75.24% year-over-year from $6.9 million in Q1 2025, and down 48.51% quarter-over-quarter from $3.3 million in Q4 2025.
Lineage Cell Therapeutics (LCTX) Current Deferred Revenue (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Current Deferred Revenue history runs 17 years deep, the most recent figure standing at $1.7 million for Q1 2026.
- In Q1 2026, Current Deferred Revenue fell 75.24% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $1.7 million (down 75.24% YoY), while the FY2025 annual figure was $3.3 million, down 54.89% from the prior year.
- Current Deferred Revenue for Q1 2026 stood at $1.7 million, down from $3.3 million in the prior quarter.
- The five-year high for Current Deferred Revenue was $45.6 million in Q1 2022, with the low at $1.7 million in Q1 2026.
- The 5-year median for Current Deferred Revenue is $9.4 million (2022), against an average of $12.2 million.
- The sharpest annual moves came in 2022 and 2023: Current Deferred Revenue surged 45048.51% in 2022, then tumbled 75.88% in 2023.
- Lineage Cell Therapeutics' Current Deferred Revenue stood at $9.4 million in 2022, then advanced by 14.72% to $10.8 million in 2023, then sank by 31.64% to $7.4 million in 2024, then sank by 54.89% to $3.3 million in 2025, then slumped by 48.51% to $1.7 million in 2026.
- Business Quant data shows LCTX's Current Deferred Revenue at $1.7 million in Q1 2026, $3.3 million in Q4 2025, and $3.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.68 Mn |
| Mar 31, 2026 | 1.72 Mn |
| Dec 31, 2025 | 3.33 Mn |
| Sep 30, 2025 | 3.77 Mn |
| Jun 30, 2025 | 5.26 Mn |
| Mar 31, 2025 | 6.93 Mn |
| Dec 31, 2024 | 7.39 Mn |
| Sep 30, 2024 | 8.25 Mn |
| Jun 30, 2024 | 9.14 Mn |
| Mar 31, 2024 | 10.11 Mn |
| Dec 31, 2023 | 10.81 Mn |
| Sep 30, 2023 | 9.92 Mn |
| Jun 30, 2023 | 10.40 Mn |
| Mar 31, 2023 | 11.00 Mn |
| Dec 31, 2022 | 9.42 Mn |
| Sep 30, 2022 | 38.90 Mn |
| Jun 30, 2022 | 15.70 Mn |
| Mar 31, 2022 | 45.60 Mn |
| Dec 31, 2021 | 18.12 Mn |
| Sep 30, 2021 | 975,000.00 |